Phenotypic Characteristics of Superlean Individuals Including Gut Microbiome
Launched by SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY ,CHINESE ACADEMY OF SCIENCES · Mar 27, 2023
Trial Information
Current as of November 13, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a specific group of very thin individuals, known as "superlean" individuals, who have a body mass index (BMI) of less than 18.5. The researchers want to learn more about what makes these people different from those with a normal BMI (between 21.5 and 25). They will look at various factors such as body composition, eating habits, hormone levels, genetics, and the bacteria that live in the gut. The goal is to gain a better understanding of why some people are superlean and how their health is affected.
To participate in the study, you need to be between 25 and 40 years old and fall into one of two groups: either superlean or in the normal BMI range. However, certain health conditions will exclude you from participation, such as metabolic diseases, eating disorders, or being treated for weight loss. If you join the study, you can expect to provide information about your eating habits and undergo tests to evaluate your body composition and gut health. This research could help improve our understanding of body weight and health behaviors in individuals.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Control group (21.5≤ BMI\<25), Superlean group (BMI≤18.5)
- • Age between 25-40 years old
- Exclusion Criteria:
- • Having metabolic diseases or eating disorders
- • Recent weight loss due to various disease causes
- • Being treated for weight loss
- • Having an infectious disease
- • Pregnant and lactating women
- • People with blood sickness, pathological hypo- or hypertension
- • People suffering from claustrophobia
- • No metal implants in the body
- • Use of antibiotics, probiotics, oral laxatives, etc. within 8 weeks
About Shenzhen Institutes Of Advanced Technology ,Chinese Academy Of Sciences
The Shenzhen Institutes of Advanced Technology (SIAT), part of the Chinese Academy of Sciences, is a leading research institution dedicated to advancing scientific knowledge and technology across various fields, including biomedical research. SIAT is committed to fostering innovation through interdisciplinary collaboration and state-of-the-art facilities, focusing on the translation of research into practical applications. With a strong emphasis on clinical trials and regulatory compliance, SIAT aims to contribute to the global healthcare landscape by developing novel therapies and solutions that address pressing medical challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shenzhen, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials